EUS-RFA for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

← ClinicalTrials.gov Studies

Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

N/A NCT07536087 Kind: NA Apr 17, 2026

Abstract

The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic neuroendocrine tumors (pNETs) in patients who are not suitable candidates for surgical treatment or who refuse surgery.

EUS-RFA, as a minimally invasive therapeutic option, may potentially reduce the need for intensive imaging surveillance, prevent further progression of these lesions, and serve as a bridging therapy in selected patients for whom surgical intervention may be considered in the future. At the same time, EUS-RFA could contribute to reducing overtreatment, thereby lowering the risk of complications associated with surgical procedures and leading to an overall reduction in healthcare costs.

The secondary objectives of the study are to evaluate the safety profile of EUS-RFA, including the incidence and severity of adverse events both in the early postoperative period and during the first year of follow-up, as well as to assess the long-term efficacy of EUS-RFA, including disease progression.

Conditions: Endoscopic Ultrasound-Guided Radiofrequency Ablation, Pancreatic Neuroendocrine Tumors (pNET), Pancreatic Cystic Neoplasms

Interventions: Endoscopic ultrasound-guided radiofrequency ablation for pancreatic cystic lesions, Endoscopic ultrasound-guided radiofrequency ablation of pancreatic solid lesions

View original document →